Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468
- PMID: 1534511
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468
Abstract
Previous studies have demonstrated that estrogen-responsive human breast cancer cells can be induced to undergo an energy-dependent, genetically programmed series of biochemical changes that result in the active suicide of the cells following estrogen ablation. In contrast, estrogen-independent human breast cancer cells do not activate this programmed cell death pathway following estrogen ablation. This could be due either to the absence of the cellular machinery required for programmed cell death or simply to the inability of estrogen ablation to activate this machinery. To discriminate between these two possibilities, the MDA-MB-468 estrogen-independent human mammary adenocarcinoma cell line was used as a model system to study the mechanism of cell death following cytotoxic drug treatment. Exposure of these cells to the fluorinated pyrimidines, 5-fluoro-2'-deoxyuridine or trifluorothymidine, resulted in growth inhibition and loss of proliferative capacity within 24 h. These changes occurred while cell membrane integrity was intact as measured by either cellular morphology or trypan blue exclusion. After 48 h of drug treatment, loss of cell membrane integrity was followed by cell lysis and a rapid decline in cell number. The addition of 16 microM thymidine prior to drug treatment prevented cell death, but thymidine did not rescue these cells once drug treatment was initiated. Analysis of DNA revealed the characteristic fragmentation into nucleosomal oligomers that is a hallmark of programmed cell death. Associated with this death pathway was a 15-fold induction of transforming growth factor beta 1 gene expression that has been previously observed in a variety of cellular systems undergoing programmed cell death. These results indicate that MDA-MB-468 estrogen-independent human mammary carcinoma cells retain the ability to undergo programmed cell death after treatment with cytotoxic drugs that induce a "thymineless" state.
Similar articles
-
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.Cancer Res. 1991 Jan 1;51(1):162-6. Cancer Res. 1991. PMID: 1899037
-
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.Cancer Res. 1990 Jun 15;50(12):3748-53. Cancer Res. 1990. PMID: 2340521
-
Programmed death of nonproliferating androgen-independent prostatic cancer cells.Cancer Res. 1991 Sep 1;51(17):4693-700. Cancer Res. 1991. PMID: 1873814
-
Androgen regulation of programmed death of normal and malignant prostatic cells.J Androl. 1992 Nov-Dec;13(6):457-64. J Androl. 1992. PMID: 1293127 Review.
-
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.Prostate. 1996 Apr;28(4):251-65. doi: 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G. Prostate. 1996. PMID: 8602401 Review.
Cited by
-
Isoform-Directed Control of c-Myc Functions: Understanding the Balance from Proliferation to Growth Arrest.Int J Mol Sci. 2023 Dec 15;24(24):17524. doi: 10.3390/ijms242417524. Int J Mol Sci. 2023. PMID: 38139353 Free PMC article. Review.
-
Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor.Br J Pharmacol. 1999 Nov;128(5):999-1010. doi: 10.1038/sj.bjp.0702879. Br J Pharmacol. 1999. PMID: 10556937 Free PMC article.
-
Therapeutic implications of the TGF-beta system.J Mammary Gland Biol Neoplasia. 1996 Oct;1(4):391-7. doi: 10.1007/BF02017395. J Mammary Gland Biol Neoplasia. 1996. PMID: 10887513 Review.
-
Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro.Invest New Drugs. 2002 Aug;20(3):229-40. doi: 10.1023/a:1016281109100. Invest New Drugs. 2002. PMID: 12201486
-
Microfilament reorganization during apoptosis: the role of Gas2, a possible substrate for ICE-like proteases.EMBO J. 1995 Nov 1;14(21):5179-90. doi: 10.1002/j.1460-2075.1995.tb00202.x. EMBO J. 1995. PMID: 7489707 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous